Ginny Blocki

Ginny Blocki

SVP, Global Marketing & Product Management

Ginny Blocki serves as the SVP, Global Marketing & Product Management of embecta. Previously, Ginny was with Baxter as the Head of US Medication Delivery Marketing (Infusion Systems, IV Fluids, Disposables and Pharmacy WorkFlow Manager). Prior to her role at Baxter, Ginny was the Vice President Specialty Products with Assertio Therapeutics where she played a key role in product development of a priority asset and multiple business development endeavors while leading marketing and sales efforts.

Before joining Assertio, Ginny served as Head of Global Marketing Molecular Diagnostics at Abbott Laboratories, overseeing and leading all commercial activities. Prior to Abbott, Ginny served as the Vice President, Head of Global Marketing Immunology with Baxter and Baxalta (spin off from Baxter) where she played a vital role in the Global Immunology business. Throughout her career, Ginny has held leadership roles of increasing responsibility in general management, marketing, strategy, market access, and sales. She has a proven track record of developing successful brands and businesses through different phases of product development, working with cross-functional teams on a regional, national, and global scale.

Ginny holds a Bachelor of Science degree in finance from Indiana University. She’s also a Kellogg School of Management alum having completed the Executive Scholar Program in General Management.

    Forward Looking Statement

    The information included on this website and other information provided from time to time through webcasts, conference calls, securities analyst meetings, road show presentations, investor conferences, transcripts, newsletters and similar events and communications contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws, based on current expectations and assumptions that involve risks and uncertainties. If the risks or uncertainties ever materialize or the assumptions prove incorrect, the results of embecta may differ materially from those expressed or implied by such forward-looking statements and assumptions.These statements use words such as "will," "plan," "expect," "anticipate," "estimate," "next," "project," "potential," "continue," "expand" and "grow" and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance and statements regarding our business strategy, impact of mergers and acquisitions,future product development, regulatory clearances and approvals, competitive position and expenditures.These statements are based on current assumptions and expectations of future events at the time they are made and thus are inherently subject to uncertainty.

    All such statements are based upon current expectations of embecta and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Many of these risks and uncertainties are beyond the company's control. For a discussion of certain factors that could cause our actual results to differ from our expectations in any forward-looking statements see our latest Annual Report on Form 10-K and other filings with the SEC. embecta expressly disclaims any undertaking to update or revise any forward looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.